Cell-Based Assay Market worth $14.8 Billion by 2018

Wednesday 14 May 2014, Amsterdam

The new market report on Cell-Based Assays, available on ASDReports, analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia-Pacific, and Rest of the World.
This report studies the global cell-based assays market over the forecast period of 2013 to 2018.

The global cell-based assay by product market is poised to reach $14.8 billion by 2018, at a CAGR of 11.1%.The major market propellants for cell-based assays are benefits of cell-based assays over biochemical assays and animal models and public-private partnerships for drug discovery. The growth market is also driven by continuous innovations and developments in the market aimed at higher throughput. The opportunities for the growth of this market include developments in emerging markets such as Asia, introduction of technologically advanced products, and increase need of toxicity screening. However, factors such as intellectual property rights are restricting innovation in the market and hence hindering growth. The optimization of assay for cell-based assay is still a challenge while complexity of HTS assays and assay standardization and validation is still an unmet need. However, some revolutionary platforms like label-free technology, 3D assays, induced pluripotent stem cells are expected to gain traction in future.

This research report categorizes and analyzes the global cell-based assay market on the basis of products, applications, end-users and geography in the cell-based assay market. All these markets are further divided into segments and sub-segments, to provide exhaustive value analysis for the years 2011, 2012, 2013, and forecast to 2018. Based on the cell-based assay product type, consumables (assay kits, reagents, microplates, cell lines), detection and screening instruments, automation and high throughput screening instruments, software and services form the overall cell-based assay market. Under applications market for cell-based assay drug discovery, ADME studies, predictive toxicology and basic research are covered. The end-users market covers academic and government institutions, pharmaceutical and biotechnology companies, and contract research organizations.
North America accounted for the largest market share of the cell-based assay market, followed by Europe, in 2013. However, Asia presents significant opportunities for investors as the developed markets get saturated.

The major players included in this report are BD Biosciences (U.S.) , Danaher Corporation (U.S.), DiscoveRx (U.S.), EMD Millipore (Germany), GE Healthcare (U.K.), Life Technologies Corporation (U.S.), PerkinElmer (U.S.), and Promega Corporation (U.S.).